NeuroBo Pharmaceuticals Inc (NRBO): Fair Value Consensus
The price action for NeuroBo Pharmaceuticals (NRBO) shown on this chart reflects market expectations for a biopharmaceutical business developing treatments for metabolic and psychiatric disorders. The current consensus stands at 26.74. The operating model relies on outsourcing medical tests to external laboratories, which minimizes internal costs. High growth potential is driven by the patenting of unique formulas, enabling the mass production of medications at low cost.
Analytical breakdowns for NeuroBo (NRBO)
- stock price and consensus target price:
- stock exchange capitalization data:
- book capitalization indicators:
- debt obligations and liquidity statistics:
Debt to Equity Ratio NeuroBo Pharmaceuticals|NRBO - Long-Term Debt to Capital|Current Liabilities to Capital NeuroBo Pharma|NRBO - Company Total Debt|Debts to Book Capitalization NeuroBo|NRBO - Company Long-Term Debt|Company Short-Term Loans and Borrowings NeuroBo Pharmaceuticals|Immediate Liquidity neurobopharma.com
- financial results and valuation multiples details:
NRBO - Company Net Income|Net Profit Forecast NeuroBo Pharmaceuticals|NRBO - P/E Multiple|Projected Price to Earnings Ratio NeuroBo Pharmaceuticals Inc|NRBO - Price/Earnings to Growth Multiple|EV/EBITDA Multiple NeuroBo|NRBO - Profit before payment of interest, taxes and amortization|Earnings per share for the trailing year NeuroBo Pharmaceuticals|NRBO - Earnings per share for the last twelve months|Earnings per share growth in annualized terms for the last twelve months neurobopharma.com|NRBO - Earnings growth in current year|Net earnings per share growth forecast for next year NeuroBo Pharmaceuticals
Summary company analytics:NRBO neurobopharma.com
The flexible contract manufacturing model of NeuroBo Pharmaceuticals (NRBO) minimizes capital expenditures, shifting the valuation focus toward the success of clinical trials for neuro-drugs. The market consensus forecast vector aggregates investment bank calculations of the asset's fair value, transforming fundamental expectations into a mathematical trajectory, which allows investors to promptly identify shifts in the long-term trend and adjust the risk premium.
Competitors of NeuroBo Pharmaceuticals
biogen.com - Broker Consensus Forecast|Price Target Chart Neurocrine Biosciences, Inc. NBIX|Fair Value Consensus RGC|Axsome Therapeutics Inc - Analyst Consensus Forecast|ACAD: Price Target Chart|Xenon Pharmaceuticals (XENE) - Price Target Chart|Average Forecast Price vikingtherapeutics.com (VKTX)|Price Target Chart Supernus|Broker Consensus Forecast CPRX (Catalyst Pharma)|Analyst Consensus Forecast DNLI|HRMY - Average Forecast Price|Biohaven Ltd. - Consensus Target|Analyst Consensus Forecast amylyx.com AMLX|TRVI - Price Target Chart|Fair Value Consensus PRAX (Praxis Precision Medicines Inc)|Anavex Corp (AVXL) - Price Target Chart|Average Forecast Price CeriBell EEG (CBLL)|Price Target Chart Prothena Corporation PLC|Broker Consensus Forecast ALEC (Alector Therapeutics)|Analyst Consensus Forecast ANNX|OMER - Average Forecast Price|Neurogene Corp - Consensus Target|Analyst Consensus Forecast AC Immune Inc ACIU|VYGR - Price Target Chart|Fair Value Consensus NMRA (neumoratx.com)|Scilex (SCLX) - Price Target Chart|Average Forecast Price Tevogen Bio Holdings Inc. (TVGN)|ACOG (Alpha Cognition Inc) - Analyst Consensus Forecast|Price Target Chart CGTX|Price Target Chart Inhibikase Therapeutics (IKT)|SAVA - Average Forecast Price|Assertio - Consensus Target|Fair Value Consensus COYA|VTGN - Price Target Chart|Forecast Levels Chart OVID|ABOS: Analyst Consensus Forecast|cervomed.com - Fair Value Consensus|ATHE (Alterity Therapeutics Ltd.) - Analyst Consensus Forecast|Analyst Consensus Forecast Clene Nanomedicine|Price Target Chart PepGen Inc. (PEPG)|JUNS (jupiterneurosciences.com) - Fair Value Consensus|Price Target Chart Relmada Therapeutics RLMD|ANVS - Consensus Target|Grace Tx - Analyst Consensus Forecast|AIFF - Analyst Consensus Forecast|KLTO: Analyst Consensus Forecast|Consensus Target NeuroSense Therapeutics Ltd.|RVPH (Reviva Pharmaceuticals) - Analyst Consensus Forecast|Average Forecast Price MetaVia, Inc. MTVA|Consensus Target NRXS (NeurAxis)|Analyst Consensus Forecast heliusmedical.com (HSDT)|Passage Bio - Consensus Target|Analyst Forecast Prices NEUP (Neuphoria Therapeutics, Inc.)|Minerva Neurosciences - Analyst Consensus Forecast|Analyst Median Target athira.com ATHA|ADXN: Analyst Consensus Forecast|Consensus Target Alzamend Neuro|CYCN (Cyclerion Therapeutics Inc.) - Analyst Consensus Forecast|Analyst Consensus Forecast Protagenic|Price Target Chart Pasithea Therapeutics (KTTA)|Price Target Chart CRGT (cortigent.com)|Price Target Chart Avenue Therapeutics, Inc. ATXI|Analyst Median Target Brainstorm Cell Therapeutics Inc. (BCLI)|CARA - Price Target Chart|CHRO (Chromocell) - Broker Consensus Forecast|eliemtx.com (ELYM) - Price Target Chart|Intra-Cellular Therapies, Inc. - Fair Value Consensus|LBPH (Longboard Pharmaceuticals, Inc.) - Analyst Consensus Forecast|Price Target Chart MRNS|Price Target Chart NKGen (NKGN)|SAGE - Average Forecast Price|Price Target Chart Synaptogenix, Inc. SNPX|TRVN: Broker Consensus Forecast|Vigil Neuro - Analyst Consensus Forecast|Average Forecast Price Anew Medical Inc.|CERE (Cerevel) - Consensus Target
